Affordable Access

Access to the full text

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Authors
  • van Tilburg, Cornelis M.1, 2, 3
  • Milde, Till1, 2, 3
  • Witt, Ruth1, 3
  • Ecker, Jonas1, 2, 3
  • Hielscher, Thomas4
  • Seitz, Angelika2
  • Schenk, Jens-Peter2
  • Buhl, Juliane L.1, 3, 5
  • Riehl, Dennis6
  • Frühwald, Michael C.7
  • Pekrun, Arnulf8
  • Rossig, Claudia9
  • Wieland, Regina10
  • Flotho, Christian11
  • Kordes, Uwe12
  • Gruhn, Bernd13
  • Simon, Thorsten14
  • Linderkamp, Christin15
  • Sahm, Felix4, 2
  • Taylor, Lenka2
  • And 7 more
  • 1 German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Im Neuenheimer Feld 430, Heidelberg, 69120, Germany , Heidelberg (Germany)
  • 2 Heidelberg University Hospital, Heidelberg, Germany , Heidelberg (Germany)
  • 3 German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg (Germany)
  • 4 German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany , Heidelberg (Germany)
  • 5 Heidelberg University, Heidelberg, Germany , Heidelberg (Germany)
  • 6 German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany , Heidelberg (Germany)
  • 7 University Children’s Hospital Augsburg, Augsburg, Germany , Augsburg (Germany)
  • 8 Children’s Hospital, Bremen, Germany , Bremen (Germany)
  • 9 University Children’s Hospital Muenster, Muenster, Germany , Muenster (Germany)
  • 10 Essen University Hospital, Essen, Germany , Essen (Germany)
  • 11 Freiburg University Hospital, Freiburg, Germany , Freiburg (Germany)
  • 12 University Medical Center Eppendorf, Hamburg, Germany , Hamburg (Germany)
  • 13 Jena University Hospital, Jena, Germany , Jena (Germany)
  • 14 Cologne University Hospital, Cologne, Germany , Cologne (Germany)
  • 15 Hannover University Hospital, Hanover, Germany , Hanover (Germany)
  • 16 German Cancer Research Center (DKFZ), Heidelberg, Germany , Heidelberg (Germany)
Type
Published Article
Journal
Clinical Epigenetics
Publisher
Springer-Verlag
Publication Date
Dec 10, 2019
Volume
11
Issue
1
Identifiers
DOI: 10.1186/s13148-019-0775-1
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundUntil today, adult and pediatric clinical trials investigating single-agent or combinatorial HDAC inhibitors including vorinostat in solid tumors have largely failed to demonstrate efficacy. These results may in part be explained by data from preclinical models showing significant activity only at higher concentrations compared to those achieved with current dosing regimens. In the current pediatric trial, we applied an intra-patient dose escalation design.The purpose of this trial was to determine a safe dose recommendation (SDR) of single-agent vorinostat for intra-patient dose escalation, pharmacokinetic analyses (PK), and activity evaluation in children (3–18 years) with relapsed or therapy-refractory malignancies.ResultsA phase I intra-patient dose (de)escalation was performed until individual maximum tolerated dose (MTD). The starting dose was 180 mg/m2/day with weekly dose escalations of 50 mg/m2 until DLT/maximum dose. After MTD determination, patients seamlessly continued in phase II with disease assessments every 3 months. PK and plasma cytokine profiles were determined. Fifty of 52 patients received treatment. n = 27/50 (54%) completed the intra-patient (de)escalation and entered phase II. An SDR of 130 mg/m2/day was determined (maximum, 580 mg/m2/day). n = 46/50 (92%) patients experienced treatment-related AEs which were mostly reversible and included thrombocytopenia, fatigue, nausea, diarrhea, anemia, and vomiting. n = 6/50 (12%) had treatment-related SAEs. No treatment-related deaths occurred. Higher dose levels resulted in higher Cmax. Five patients achieved prolonged disease control (> 12 months) and showed a higher Cmax (> 270 ng/mL) and MTDs. Best overall response (combining PR and SD, no CR observed) rate in phase II was 6/27 (22%) with a median PFS and OS of 5.3 and 22.4 months. Low levels of baseline cytokine expression were significantly correlated with favorable outcome.ConclusionAn SDR of 130 mg/m2/day for individual dose escalation was determined. Higher drug exposure was associated with responses and long-term disease stabilization with manageable toxicity. Patients with low expression of plasma cytokine levels at baseline were able to tolerate higher doses of vorinostat and benefited from treatment. Baseline cytokine profile is a promising potential predictive biomarker.Trial registrationClinicalTrials.gov, NCT01422499. Registered 24 August 2011,

Report this publication

Statistics

Seen <100 times